A team of collaborators drawn from Harvard, Johnson & Johnson and other groups published results from a preclinical animal study Thursday afternoon that underscores the potential for developing the world's first HIV vaccine.
J&J's Janssen unit is recalling one lot of Ortho-Cept tablets because of the potential that the potency of the two active ingredients may not meet specifications, Health Canada reports.
San Diego biotech Ichor Medical Systems stands to earn up to $85 million, plus royalties, if its new partnership with Johnson & Johnson's Janssen hits the right notes. The companies announced plans this week to develop DNA vaccines for hepatitis B using Ichor's TriGrid electroporation technology for clinical administration.
After securing U.S. rights to Janssen's Nucynta franchise in mid-January this year, Depomed has now raised enough to pay for it in full. Nucynta fits nicely into Depomed's cadre of pain and neurological treatments, and the Newark, CA-based company's Acuform drug delivery tech already gives Nucynta an edge as an oral treatment.
In bid to improve patient adherence, the U.S. National Institutes of Health is funding and helping run two clinical trials of long-acting injectable HIV candidates being developed by Johnson & Johnson's Janssen and GlaxoSmithKline.
Did Johnson & Johnson hide Risperdal's potential to trigger breast growth in boys? Or did the drugmaker adequately disclose the potential side effect? A Philadelphia jury is literally out deliberating on these two questions.
Johnson & Johnson's Janssen unit is teaming up with nonprofit JDRF to develop new diagnostic approaches for Type 1 diabetes, aiming to identify the disease earlier and curb its progression.
Johnson & Johnson's Janssen unit has agreed to offer England's National Health Service a money-back guarantee on its hep C fighter Olysio, even as the treatment won approval from the cost watchdog there.
Earlier this week, once-skeptical Johnson & Johnson CEO Alex Gorsky seemed to be fully on-board pharma's slim-down bandwagon, telling presentation-watchers at the JP Morgan Healthcare Conference he was willing to jettison pieces of the J&J puzzle if they didn't present a "path to achieving leadership." Now, he's followed up with another divestment that will send U.S. rights to pain med Nucynta to California's Depomed.
J&J subsidiary Janssen Biotech has inked a deal to collaborate with Boston-based Vedanta on a new bacterial treatment for inflammatory bowel disease, or IBD. And it handed over an undisclosed upfront payment and promises of up to $241 million in milestones if their partnership can blaze a path to the market eventually.